Want to see JP:4584 full AI Analyst Report?
4584 Stock Chart & Stats
¥203.00
¥2.00(1.89%)
At close: 4:00 PM EST
¥203.00
¥2.00(1.89%)
Day’s Range― - ―
52-Week Range¥125.00 - ¥363.00
Previous CloseN/A
Volume149.00K
Average Volume (3M)766.13K
Market Cap
¥7.33B
Enterprise Value¥11.31K
Total Cash (Recent Filing)¥3.29B
Total Debt (Recent Filing)¥2.55B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.28
Shares Outstanding50,582,990
10 Day Avg. Volume871,200
30 Day Avg. Volume766,126
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.17
Price to Sales (P/S)1.80
P/FCF Ratio-10.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)19.3
Revenue Forecast (FY)¥4.92B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue expansion from ~¥1.0B to ~¥6.6B over the period indicates durable commercial traction and successful commercialization execution. Sustained top-line scaling reduces single-product risk, supports operating leverage as volumes grow, and creates a stronger foundation for future margin recovery and reinvestment.
Biosimilars-focused Business ModelA strategic focus on biosimilars and biologics aligns with structural industry trends toward cost-effective biologic alternatives and established regulatory pathways. This specialization creates identifiable market demand, potential partnerships, and repeatable commercialization playbooks that can support sustainable revenue opportunities over multiple years.
Demonstrated Cash Generation In 2025Producing nearly ¥0.9B of operating and free cash flow in 2025 shows the business can convert sales into cash when execution aligns. That demonstrated cash generation proves the commercial model's viability, supports potential self-funding of programs in favorable years, and provides a template for restoring consistent cash flow with stable operations.
Bears Say
Elevated LeverageMaterial leverage increases refinancing and interest-rate exposure for a company that is not consistently profitable. Elevated debt-to-equity restricts strategic flexibility, raises fixed costs, and magnifies downside risk during revenue or margin setbacks, making sustained investment or R&D financing more contingent on external funding.
Recurrent Cash BurnA switch from positive cash generation to ~¥1.1B of operating and free cash burn in 2026 highlights unstable cash dynamics. Persistent negative operating cash flow elevates dilution or refinancing risk, limits ability to fund capex or commercialization without external capital, and undermines long-term financial resilience.
Inconsistent Profitability And Negative ReturnsVolatile margins and recurring net losses reflect an inability to consistently translate revenue growth into sustainable profits. Negative ROE and compressed gross margins reduce internal capital formation, weaken investor confidence in operating leverage, and indicate the company may struggle to achieve durable profitability without structural cost or product-mix improvements.
Kidswell Bio Corporation News
4584 FAQ
What was Kidswell Bio Corporation’s price range in the past 12 months?
Kidswell Bio Corporation lowest stock price was ¥125.00 and its highest was ¥363.00 in the past 12 months.
What is Kidswell Bio Corporation’s market cap?
Kidswell Bio Corporation’s market cap is ¥7.33B.
When is Kidswell Bio Corporation’s upcoming earnings report date?
Kidswell Bio Corporation’s upcoming earnings report date is Aug 13, 2026 which is in 19 days.
How were Kidswell Bio Corporation’s earnings last quarter?
Kidswell Bio Corporation released its earnings results on May 14, 2026. The company reported -¥5.54 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kidswell Bio Corporation overvalued?
According to Wall Street analysts Kidswell Bio Corporation’s price is currently Overvalued.
Does Kidswell Bio Corporation pay dividends?
Kidswell Bio Corporation does not currently pay dividends.
What is Kidswell Bio Corporation’s EPS estimate?
Kidswell Bio Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kidswell Bio Corporation have?
Kidswell Bio Corporation has 50,582,990 shares outstanding.
What happened to Kidswell Bio Corporation’s price movement after its last earnings report?
Kidswell Bio Corporation reported an EPS of -¥5.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.203%.
Which hedge fund is a major shareholder of Kidswell Bio Corporation?
Currently, no hedge funds are holding shares in JP:4584
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kidswell Bio Corporation
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―